Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

Jul 27, 2016
340 Pages - Pub ID: KLI15068137
Share this report
 
Online Download $995
Departmental Site License (one location, 10 users) $1,495
Global Site License $1,990

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025



The pharmaceutical market has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report provides:
  • Corporate Summary
  • Total Company Revenue and Total R&D Spending 2011-2015
  • Break-up of Sales by Region, 2015
  • Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
  • Leading Pharmaceutical Products, 2015 Sales
  • Late Stage Product Pipeline
  • Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
  • Corporate Development Details
The top 25 pharmaceutical companies included in the study are:
  • AbbVie
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Daiichi Sankyo
  • Eli Lilly & Co.
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Novartis
  • Novo Nordisk
  • Otsuka Pharmaceutical
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • TEVA
Despite the new approaches, new technologies and a wealth of new information, drug R&D is still challenged by understanding exactly how drugs will work and why they may fail. Target validation remains a quandary as well. Thus, the hurdle of getting past Phase III trials and launching more NMEs continues. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:
  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • The Role of Contract Research Organizations
The report also looks at market trends and values by therapeutic area, providing information on the following segments:
  • Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
  • Top 5 Neurotherapeutic Companies, 2015 Sales
  • Top 5 Infection Treatment Companies, 2015 Sales
  • Top 5 Oncology Companies, 2015 Sales
  • Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
  • Top 5 Other Drug Companies, 2015 Sales
In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. Data provided include:
  • Global Pharmaceutical Projects in Development by Therapeutic Segment
  • Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market % Change by Therapeutic Segment, 2014-2015
  • Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
  • Top Companies by 2015 Pharmaceutical Sales Growth
  • Global Pharmaceutical Market, Sales Growth by Company, 2014- 2015
  • Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales, 2015 Compared to 2011 and 2013
  • Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
  • Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025—based on late stage development projects evaluated
  • Evaluating Pharmaceutical Company Growth, 2015-2025
  • Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
  • International Population Trend Age 65+
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals, diagnostics, devices, chemicals, agriculture and animal health. These are areas where many of these companies also compete with significant market shares.

Also, despite an in-depth interview process and complete review of the top 25 pharmaceutical companies' financials and literature, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical sales are not discussed.

This report provides long-term company sales forecasts, which are based on 2015 market conditions. Company forecasts were derived from a combination of pipeline analyses, current product reviews, patent and exclusivity activities, recent merger and alliance impacts, and a number of other factors discovered throughout the writing of this report.
ONE: Executive Summary
Introduction
Scope and Methodology
Future Market Opportunity
Leading Companies
Conclusions
TWO: Introduction
Global Pharmaceutical Market
Top 25 Pharmaceutical Companies: An Overview
Global Healthcare Spending
Aging Population and Impact on Pharmaceutical Markets
THREE: Trends in Pharmaceutical Research and Development
Pharmaceutical Research & Development Challenge
The Drug Approval Process
Percent of Approvals
Selecting Better Targets
Top R&D Spenders
The Pipeline Snapshot
Expanded Options in Treating Diseases
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Breakthrough Therapy
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
The Role of Contract Research Organizations
FOUR: Pfizer, Inc.
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
FIVE: Novartis International AG
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
SIX: Roche Ltd.
Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
SEVEN: Merck & Co., Inc.
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
EIGHT: Sanofi
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
NINE: Gilead Sciences
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TEN: Johnson & Johnson
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
ELEVEN: GlaxoSmithKline plc
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWELVE: AstraZeneca plc
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
THIRTEEN: AbbVie, Inc.
Company Overview
Financial Performance and Investments
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
FOURTEEN: Amgen, Inc.
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
FIFTEEN: TEVA Pharmaceutical Industries, Ltd.
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
SIXTEEN: Eli Lilly and Company
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
SEVENTEEN: Bristol-Myers Squibb Company
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
EIGHTEEN: Novo Nordisk
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
NINETEEN: Bayer AG
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY: Takeda Pharmaceutical Co., Ltd.
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY-ONE: Boehringer Ingelheim GmbH
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY-TWO: Allergan PLC
Company Overview
Company Financial Performance and Investments
Pharmaceutical Business Performance
Late Stage Pipeline
Growth Strategy
TWENTY-THREE: Astellas Pharma, Inc.
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY-FOUR: Mylan, Inc.
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Pipeline
Growth Strategy
TWENTY-FIVE: Biogen, Inc.
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Pipeline
Growth Strategy
TWENTY-SIX: Celgene Corporation
Company Overview
Company Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY-SEVEN: Otsuka Pharmaceutical
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY-EIGHT: Daiichi Sankyo
Company Overview
Financial Performance and Investments
Geographic Market Participation
Pharmaceutical Business Performance
Leading Products
Late Stage Pipeline
Growth Strategy
TWENTY-NINE: Market Summary and Forecast Analysis
Company Overview
Market Trends and Values by Therapeutic Area
Cardiovascular/Blood Market Analysis
Neurotherapeutics Market Analysis
Infection Treatments Market Analysis
Oncology Market Analysis
Respiratory and Inflammation Market Analysis
Other Drug Market Analysis
Evaluating Changes in 2015 Market Value
Year-over-Year Growth Analysis
Company Analysis
Market Forecast
Future Company Outlook
LIST OF EXHIBITS
ONE: Executive Summary
Table 1-1: Global Pharmaceutical Projects in Development by Therapeutic Segment
Figure 1-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
Table 1-2: Leading Pharmaceutical Companies
TWO: Introduction
Figure 2-1: Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
Table 2- 1: Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
Figure 2-2: Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales2015
Table 2-2: Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates
Figure 2-3: International Population Trend Age 65+
THREE: Trends in Pharmaceutical Research and Development
Table 3-1: Phases of Clinical Drug Development
Table 3-2: Top R&D Spenders in the Pharmaceutical Industry 2013, 2014 and2015
Figure 3-1: Top 10 R&D Spenders in the Pharmaceutical Industry, 2015 Comparison by Company
Figure 3-2: Company Pipelines by Total Late Stage Development Projects (Top 25 Companies by Revenues)
Figure 3-3: Cardiovascular/Blood Pipeline Leaders, 2015
Figure 3-4: Neurotherapeutics Pipeline Leaders, 2015
Figure 3-5: Infectious Disease Pipeline Leaders, 2015
Figure 3-6: Oncology Pipeline Leaders, 2015
Figure 3-7: Respiratory/Inflammation Pipeline Leaders, 2015
Figure 3-8: Other Therapy Pipeline Leaders, 2015
Table 3-3: Orphan Drug Designations Granted and Approved by the FDA 1983-2016
Table 3-4: Examples of Fast-Track Drugs Withdrawn from Market
FOUR: Pfizer, Inc.
Table 4-1: Pfizer Corporate Summary
Table 4-2: Pfizer: Total Company Revenue and Total R&D Spending 2011-2015
Figure 4-1: Pfizer: Break-up of Total Revenues by Region, 2015
Figure 4-2: Pfizer: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 4-3: Pfizer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 4-3: Pfizer: Leading Pharmaceutical Products, 2015 Sales
Table 4-4: Pfizer: Late Stage Product Pipeline
Figure 4-4: Pfizer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
Table 4-5: Highlighted Corporate Developments
FIVE: Novartis International AG
Table 5-1: Novartis Corporate Summary
Table 5-2: Novartis: Total Company Revenue and Total R&D Spending 2011-2015
Figure 5-1: Novartis: Break-up of Sales by Region, 2015
Figure 5-2: Novartis: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 5-3: Novartis: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 5-3: Novartis: Leading Pharmaceutical Products, 2015 Sales
Table 5-4: Novartis: Late Stage Product Pipeline
Figure 5-4: Novartis: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 5-5: Highlighted Corporate Developments
SIX: Roche Ltd.
Table 6-1: Roche Corporate Summary
Table 6-2: Roche: Total Company Revenue and Total R&D Spending 2011-2015
Figure 6-1: Roche: Break-up of Sales by Region, 2015
Figure 6-2: Roche: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 6-3: Roche: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 6-3: Roche: Leading Pharmaceutical Products, 2015 Sales
Table 6-4: Roche: Late Stage Product Pipeline
Figure 6-4: Roche: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 6-5: Highlighted Corporate Developments
SEVEN: Merck & Co., Inc.
Table 7-1: Merck Corporate Summary
Table 7-2: Merck: Total Company Revenue and Total R&D Spending 2011-2015
Figure 7-1: Merck: Break-up of Sales by Region, 2015
Figure 7-2: Merck: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 7-3: Merck: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 7-3: Merck: Leading Pharmaceutical Products, 2015 Sales
Table 7-4: Merck: Late Stage Product Pipeline
Figure 7-4: Merck: Late Stage Product Pipeline by Therapeutic
Area-Comparing 2009, 2011, 2013 and 2015
Table 7-5: Highlighted Corporate Developments
EIGHT: Sanofi
Table 8-1: Sanofi Corporate Summary
Table 8-2: Sanofi Total Company Revenue and Total R&D Spending 2011-2015
Figure 8-1: Sanofi: Break-up of Sales by Region, 2015
Figure 8-2: Sanofi: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 8-3: Sanofi: Pharmaceutical Segment Sales 􀀀 2011 through 2015 and Forecasted 2025
Table 8-3: Sanofi: Leading Pharmaceutical Products, 2015 Sales
Table 8-4: Sanofi Late Stage Product Pipeline
Figure 8-4: Sanofi: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
Table 8-5: Highlighted Corporate Developments
NINE: Gilead Sciences
Table 9-1: Gilead Sciences Corporate Summary
Table 9-2: Gilead Sciences: Total Company Revenue and Total R&D Spending2011-2015
Figure 9-1: Gilead Sciences: Break-up of Sales by Region, 2015
Figure 9-2: Gilead Sciences: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 9-3: Gilead Sciences: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 9-3: Gilead Sciences: Leading Pharmaceutical Products, 2015 Sales
Table 9-4: Gilead Sciences: Late Stage Product Pipeline
Figure 9-4: Gilead Sciences: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
Table 9-5: Gilead Sciences: Highlighted Corporate Developments
TEN: Johnson & Johnson
Table 10-1: Johnson & Johnson Corporate Summary
Table 10-2: Johnson & Johnson: Total Company Revenue and Total R&D Spending 2011-2015
Figure 10-1: Johnson & Johnson: Break-up of Sales by Region, 2015
Figure 10-2: Johnson & Johnson: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 10-3: Johnson & Johnson: Pharmaceutical Segment Sales 2011 through2015 and Forecasted 2025
Table 10-3: Johnson & Johnson: Leading Pharmaceutical Products, 2015 Sales
Table 10-4: Johnson & Johnson: Late Stage Product Pipeline
Figure 10-4: Johnson & Johnson: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 10-5: Highlighted Corporate Developments
ELEVEN: GlaxoSmithKline plc
Table 11-1: GlaxoSmithKline Corporate Summary
Table 11-2: GlaxoSmithKline: Total Company Revenue and Total R&D Spending2011-2015
Figure 11-1: GlaxoSmithKline: Break-up of Sales by Region, 2015
Figure 11-2: GlaxoSmithKline: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 11-3: GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through2015 and Forecasted 2025
Table 11-3: GlaxoSmithKline: Leading Pharmaceutical Products, 2015 Sales
Table 11-4: GlaxoSmithKline: Late Stage Product Pipeline
Figure 11-4: GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 11-5: Highlighted Corporate Developments
TWELVE: AstraZeneca plc
Table 12-1: AstraZeneca Corporate Summary
Table 12-2: AstraZeneca: Total Company Revenue and Total R&D Spending2011-2015
Figure 12-1: AstraZeneca: Break-up of Sales by Region, 2015
Figure 12-2: AstraZeneca: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 12-3: AstraZeneca: Pharmaceutical Segment Sales 2011 through 2015
and Forecasted 2025
Table 12-3: AstraZeneca: Leading Pharmaceutical Products, 2015 Sales
Table 12-4: AstraZeneca: Late Stage Product Pipeline
Figure 12-4: AstraZeneca: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013and 2015
Table 12-5: Highlighted Corporate Developments
THIRTEEN: AbbVie, Inc.
Table 13-1: AbbVie Corporate Summary
Table 13-2: AbbVie: Total Company Revenue and Total R&D Spending 2011-2015
Figure 13-1: AbbVie: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 13-2: AbbVie: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 13-3: AbbVie: Leading Pharmaceutical Products, 2015 Sales
Table 13-4: AbbVie: Late Stage Product Pipeline
Figure 13-3: AbbVie: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 13-5: Highlighted Corporate Developments
FOURTEEN: Amgen, Inc.
Table 14-1: Amgen Corporate Summary
Table 14-2: Amgen: Total Company Revenue and Total R&D Spending 2011-2015
Figure 14-1: Amgen: Break-up of Sales by Region, 2015
Figure 14-2: Amgen: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 14-3: Amgen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 14-3: Amgen: Leading Pharmaceutical Products, 2015 Sales
Table 14-4: Amgen: Late Stage Product Pipeline
Figure 14-4: Amgen: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 14-5: Highlighted Corporate Developments
FIFTEEN: TEVA Pharmaceutical Industries, Ltd.
Table 15-1: Teva Pharmaceutical Corporate Summary
Table 15-2: Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2011-2015
Figure 15-1: Teva Pharmaceutical: Break-up of Sales by Region, 2015
Figure 15-2: Teva Pharmaceutical: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 15-3: Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 15-3: Teva Pharmaceutical: Leading Pharmaceutical Products, 2015 Sales
Table 15-4: Teva Pharmaceutical: Late Stage Product Pipeline-Brand
Development
Figure 15-4: Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics)-Comparing 2009, 2011, 2013 and 2015
Table 15-5: Highlighted Corporate Developments
SIXTEEN: Eli Lilly and Company
Table 16-1: Eli Lilly Corporate Summary
Table 16-2: Eli Lilly’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 16-1: Eli Lilly & Co.: Break-up of Sales by Region, 2015
Figure 16-2: Eli Lilly & Co.: Pharmaceutical Business Performance, 2011-2015
and Forecasted 2025
Figure 16-3: Eli Lilly & Co.: Pharmaceutical Segment Sales 2011 through 2015
and Forecasted 2025
Table 16-3: Eli Lilly & Co.: Leading Pharmaceutical Products, 2015 Sales
Table 16-4: Eli Lilly: Late Stage Product Pipeline
Figure 16-4: Eli Lilly & Co.: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 16-5: Highlighted Corporate Developments
SEVENTEEN: Bristol-Myers Squibb Company
Table 17-1: Bristol-Myers Squibb Corporate Summary
Table 17-2: Bristol-Myers Squibb’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 17-1: Bristol-Myers Squibb: Break-up of Sales by Region, 2015
Figure 17-2: Bristol-Myers Squibb: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025,($millions)
Figure 17-3: Bristol-Myers Squibb: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 17-3: Bristol-Myers Squibb: Leading Pharmaceutical Products, 2015 Sales
Table 17-4: Bristol-Myers Squibb: Late Stage Product Pipeline
Table 17-5: Bristol-Myers Squibb Highlighted Corporate Developments
EIGHTEEN: Novo Nordisk
Table 18-1: Novo Nordisk Corporate Summary
Table 18-2: Novo Nordisk: Total Company Revenue and Total R&D Spending 2011-2015
Figure 18-1: Novo Nordisk: Break-up of Sales by Region, 2015
Figure 18-2: Novo Nordisk: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 18-3: Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 18-3: Novo Nordisk: Leading Pharmaceutical Products, 2015 Sales
Table 18-4: Novo Nordisk: Late Stage Product Pipeline
Figure 18-4: Novo Nordisk: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 18-5: Highlighted Corporate Developments
NINETEEN: Bayer AG
Table 19-1: Bayer Corporate Summary
Table 19-2: Bayer’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 19-1: Bayer: Break-up of Sales by Region, 2015
Figure 19-2: Bayer: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 19-3: Bayer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 19-3: Bayer: Leading Pharmaceutical Products, 2015 Sales
Table 19-4: Bayer: Late Stage Product Pipeline
Figure 19-4: Bayer: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 19-5: Highlighted Corporate Developments
TWENTY: Takeda Pharmaceutical Co., Ltd.
Table 20-1: Takeda Corporate Summary
Table 20-1: Takeda’s Total Company Revenue and Total R&D Spending 2011-2015
Figure 20-1: Takeda: Break-up of Sales by Region, 2015
Figure 20-2: Takeda: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 20-3: Takeda: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 20-3: Takeda: Leading Pharmaceutical Products, 2015 Sales
Table 20-4: Takeda Pharmaceutical: Late Stage Product Pipeline
Figure 20-4: Takeda: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 20-5: Highlighted Corporate Developments
TWENTY-ONE: Boehringer Ingelheim GmbH
Table 21-1: Boehringer Ingelheim Corporate Summary
Table 21-2: Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2011-2015
Figure 21-1: Boehringer Ingelheim: Break-up of Sales by Region, 2015
Figure 21-2: Boehringer Ingelheim: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 21-3: Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 21-3: Boehringer Ingelheim: Leading Pharmaceutical Products, 2015 Sales
Table 21-4: Boehringer Ingelheim: Late Stage Product Pipeline
Figure 21-4: Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 21-5: Highlighted Corporate Developments
TWENTY-TWO: Allergan PLC
Table 22-1: Allergan plc Corporate Summary
Table 22-2: Allergan: Total Company Revenue and Total R&D Spending 2011-2015
Figure 22-1: Allergan: Pharmaceutical Business Performance, 2014-2015 and Forecasted 2025
Figure 22-2: Allergan: Pharmaceutical Segment Sales 2014 - 2015 and Forecasted 2025
Table 22-3: Allergan: Late Stage Product Pipeline-Brand Development
Table 22-4: Allergan: Highlighted Corporate Developments
TWENTY-THREE: Astellas Pharma, Inc.
Table 23-1: Astellas Corporate Summary
Table 23-2: Astellas: Total Company Revenue and Total R&D Spending 2011-2015
Figure 23-1: Astellas: Break-up of Sales by Region, 2015
Figure 23-2: Astellas: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 23-3: Astellas: Pharmaceutical Segment Sales 2011 through 2015 and
Forecasted 2025
Table 23-3: Astellas: Leading Pharmaceutical Products, 2015 Sales
Table 23-4: Astellas: Late Stage Product Pipeline
Figure 23-4: Astellas: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 23-5: Highlighted Corporate Developments
TWENTY-FOUR: Mylan, Inc.
Table 24-1: Mylan Corporate Summary
Table 24-2: Mylan: Total Company Revenue and Total R&D Spending 2011-2015
Figure 24-1: Mylan: Break-up of Sales by Region, 2015
Figure 24-2: Mylan: Pharmaceutical Business Performance, 2011-2015 and
Forecasted 2025
Figure 24-3: Mylan: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 24-4: Corporate Development Details
TWENTY-FIVE: Biogen, Inc.
Table 25-1: Biogen Corporate Summary
Table 25-2: Biogen: Total Company Revenue and Total R&D Spending 2011-2015
Figure 25-1: Biogen: Break-up of Sales by Region, 2015
Figure 25-2: Biogen: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 25-3: Biogen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 25-3: Biogen: Leading Pharmaceutical Products, 2015 Sales
Table 25-4: Biogen: Late Stage Product Pipeline
Figure 25-4: Biogen: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011 and 2013
Table 25-5: Biogen: Highlighted Corporate Developments
TWENTY-SIX: Celgene Corporation
Table 26-1: Celgene Corporate Summary
Table 26-2: Celgene: Total Company Revenue and Total R&D Spending 2011-2015
Figure 26-1: Celgene: Break-up of Sales by Region, 2015
Figure 26-2: Celgene: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 26-3: Celgene: Pharmaceutical Segment Sales 2011 through 2015 and
Forecasted 2025
Table 26-3: Celgene: Leading Pharmaceutical Products, 2015 Sales
Table 26-4: Celgene: Late Stage Product Pipeline
Figure 26-4: Celgene: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 26-5: Celgene: Corporate Development Details
TWENTY-SEVEN: Otsuka Pharmaceutical
Table 27-1: Otsuka Corporate Summary
Table 27-2: Otsuka Holdings: Total Company Revenue and Total R&D Spending2011-2015
Figure 27-1: Otsuka Holdings: Break-up of Sales by Region, 2015
Figure 27-2: Otsuka Holdings: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2023
Figure 27-3: Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 27-3: Otsuka Holdings: Leading Pharmaceutical Products, 2015 Sales
Table 27-4: Otsuka Holdings: Late Stage Product Pipeline
Figure 27-4: Otsuka Holdings: Late Stage Product Pipeline by Therapeutic
Area-Comparing 2009, 2011, 2013 and 2015
Table 27-5: Highlighted Corporate Developments
TWENTY-EIGHT: Daiichi Sankyo
Table 28-1: Daiichi Sankyo Corporate Summary
Table 28-2: Daiichi Sankyo: Total Company Revenue and Total R&D Spending2011-2015
Figure 28-1: Daiichi Sankyo: Break-up of Sales by Region, 2015
Figure 28-2: Daiichi Sankyo: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
Figure 28-3: Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
Table 28-3: Daiichi Sankyo: Leading Pharmaceutical Products, 2015 Sales
Table 28-4: Daiichi Sankyo: Late Stage Product Pipeline
Figure 28-4: Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
Table 28-5: Highlighted Corporate Developments
TWENTY-NINE: Market Summary and Forecast Analysis
Table 29-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
Figure 29-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
Figure 29-2: Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
Figure 29-3: Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
Figure 29-4: Top 5 Neurotherapeutic Companies, 2015 Sales
Figure 29-5: Top 5 Infection Treatment Companies, 2015 Sales
Figure 29-6: Top 5 Oncology Companies, 2015 Sales
Figure 29-6: Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
Figure 29-7: Top 5 Other Drug Companies, 2015 Sales
Figure 29-8: Global Pharmaceutical Market % Change by Therapeutic Segment,2014- 2015
Table 29-2: Top Companies by 2015 Pharmaceutical Sales Growth
Figure 29-9: Global Pharmaceutical Market, Sales Growth by Company, 2014-2015
Table 29-3: Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales2015 Compared to 2011 and 2013
Table 29-4: Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
Table 29-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,2025—based on late stage development projects evaluated
Figure 29-11: Global Pharmaceutical Market Forecast by Therapeutic Segment,2025—based on late stage development projects evaluated
Table 29-6: Evaluating Pharmaceutical Company Growth, 2015-2025

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.